FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION


Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of


the Securities Exchange Act of 1934

 

 

 

For period ending 15 December 2017

 

GlaxoSmithKline plc

(Name of registrant)


 

 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)


 

 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F


 

 

 

Form 20-F x     Form 40-F


 

--


 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.


 

 

 

Yes      No x

 

 

 

 

Transfer of Treasury Shares

 

GlaxoSmithKline plc

(the 'Company')

 

Notification of Transfer of Shares out of Treasury

 

 

On 14 December 2017, the Company transferred 38,600,000 ordinary shares of 25 pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") to BNY Mellon, the depositary of the Company's American depositary receipts ("ADR") programme, to procure the issuance and transfer of 19,300,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the "Trust") to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee for the Company procuring the issuance and transfer of the ADRs to the Trust was $35.58 per ADR, representing $17.79 per Ordinary Share, which was funded by a contribution to the Trust from GlaxoSmithKline LLC.

 

Following the transfer, the Company's issued share capital consisted of 5,372,504,800 Ordinary Shares, of which 414,605,950 were held as Treasury Shares.

 

Therefore, the total number of voting rights in the Company is 4,957,898,850. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

V A Whyte

Company Secretary

 

15 December 2017

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.


	GlaxoSmithKline plc
	(Registrant)
Date: December 15, 2017
	By: VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GlaxoSmithKline plc